OS4.4 Hypofractionated stereotactic radiotherapy and anti-PDL1 Durvalumab combination in recurrent glioblastoma: Results of the phase I part of the phase I/II STERIMGLI trial

Tekijä Pouessel, D, Mervoyer, A, Larrieu-Ciron, D, Cabarrou, B, Robert, M, Frenel, J, Olivier, P, Mounier, M, Cohen-Jonathan Moyal, E
Julkaisussa Neuro Oncol (2019)

P20.01 MEVITEM: A European, randomized, open-label Phase I/II study of vismodegib in combination with temozolomide versus temozolomide alone in adult patients with recurrent or ref...

Tekijä Frappaz, D., Meyronnet, D., Garin, G., Laigle-Donadey, F., Le Rhun, E., Bonneville-Levard, A., Frenel, J., Idbaih, A., Gourmelon, C., Chinot, O.
Julkaisussa Neuro Oncol (2016)

Prognostic impact of syndecan-1 expression in invasive ductal breast carcinomas

Tekijä Loussouarn, D, Campion, L, Sagan, C, Frenel, J-S, Dravet, F, Classe, J-M, Pioud-Martigny, R, Berton-Rigaud, D, Bourbouloux, E, Mosnier, J-F, Bataille, F-R, Campone, M
Julkaistu 2008

P04.12 Characteristics of IDH-mutant gliomas with non-canonical IDH mutations

Tekijä Poetsch, L, Dehais, C, Frénel, J, Siegfried, A, Lacomme, S, Seizeur, R, Larrieu-Ciron, D, Cappellen, D, Loussouarn, D, Ferec, C, Eimer, S, Carpentier, C, Sanson, M, Delattre, J, Figarella-Branger, D, Ducray, F, Bronnimann, C
Julkaisussa Neuro Oncol (2019)

P11.08 Defining EGFR amplification status for clinical trial inclusion

Tekijä French, P, Eoli, M, Sepulveda, J, de Heer, I, Kros, J M, Walenkamp, A, Frenel, J, Franceschi, E, Clement, P, Weller, M, Ansell, P, Looman, J, Bain, E, Morfouace, M, Gorlia, T, van den Bent, M
Julkaisussa Neuro Oncol (2019)

OS4.3 Feasibility and benefit of Molecular Profiling to Guide Enrollment of Patients with Recurrent Gliomas in Early Phase Trials

Tekijä Baldini, C, Younan, N, Castanon Alvarez, E, Bahleda, R, Hollebecque, A, Dhermain, F, Ammari, S, Alentorn, A, Dumont, S, Frenel, J, Di Stefano, A, Bielle, F, Hoang-Xuan, K, Delattre, J, Soria, J, Sanson, M, Idbaih, A, Massard, C, Touat, M
Julkaisussa Neuro Oncol (2019)